1. Executive Summary
1.1. Global Treponema Pallidum Tests Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Treponema Pallidum Tests Market Outlook, 2018 - 2031
3.1. Global Treponema Pallidum Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Treponemal test
3.1.1.1.1. Treponema Pallidum Particle Agglutination Assay (TP-PA) Test
3.1.1.1.2. Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test
3.1.1.1.3. Treponema Pallidum Hemagglutination Assay (TPHA)
3.1.1.1.4. Others
3.1.1.2. Non-treponemal tests
3.1.1.2.1. Venereal Disease Research Laboratory (VDRL) Test
3.1.1.2.2. Rapid Plasma Reagin (RPR) Test
3.1.1.2.3. Toluidine Red Unheated Serum Test (TRUST)
3.2. Global Treponema Pallidum Tests Market Outlook, by Service Provider, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Hospitals
3.2.1.2. Specialty Clinics
3.2.1.3. Ambulatory Surgical Centers
3.2.1.4. Diagnostic Laboratories
3.2.1.5. Academic & Research Institutes
3.3. Global Treponema Pallidum Tests Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Treponema Pallidum Tests Market Outlook, 2018 - 2031
4.1. North America Treponema Pallidum Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Treponemal test
4.1.1.1.1. Treponema Pallidum Particle Agglutination Assay (TP-PA) Test
4.1.1.1.2. Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test
4.1.1.1.3. Treponema Pallidum Hemagglutination Assay (TPHA)
4.1.1.1.4. Others
4.1.1.2. Non-treponemal tests
4.1.1.2.1. Venereal Disease Research Laboratory (VDRL) Test
4.1.1.2.2. Rapid Plasma Reagin (RPR) Test
4.1.1.3. Toluidine Red Unheated Serum Test (TRUST)
4.2. North America Treponema Pallidum Tests Market Outlook, by Service Provider, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Hospitals
4.2.1.2. Specialty Clinics
4.2.1.3. Ambulatory Surgical Centers
4.2.1.4. Diagnostic Laboratories
4.2.1.5. Academic & Research Institutes
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Treponema Pallidum Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
4.3.1.2. U.S. Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
4.3.1.3. Canada Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
4.3.1.4. Canada Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Treponema Pallidum Tests Market Outlook, 2018 - 2031
5.1. Europe Treponema Pallidum Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Treponemal test
5.1.1.1.1. Treponema Pallidum Particle Agglutination Assay (TP-PA) Test
5.1.1.1.2. Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test
5.1.1.1.3. Treponema Pallidum Hemagglutination Assay (TPHA)
5.1.1.1.4. Others
5.1.1.2. Non-treponemal tests
5.1.1.2.1. Venereal Disease Research Laboratory (VDRL) Test
5.1.1.2.2. Rapid Plasma Reagin (RPR) Test
5.1.1.3. Toluidine Red Unheated Serum Test (TRUST)
5.2. Europe Treponema Pallidum Tests Market Outlook, by Service Provider, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Hospitals
5.2.1.2. Specialty Clinics
5.2.1.3. Ambulatory Surgical Centers
5.2.1.4. Diagnostic Laboratories
5.2.1.5. Academic & Research Institutes
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Treponema Pallidum Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Germany Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.2. Germany Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.1.3. U.K. Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.4. U.K. Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.1.5. France Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.6. France Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.1.7. Italy Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.8. Italy Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.1.9. Turkey Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.10. Turkey Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.1.11. Russia Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.12. Russia Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.1.13. Rest of Europe Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
5.3.1.14. Rest of Europe Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Treponema Pallidum Tests Market Outlook, 2018 - 2031
6.1. Asia Pacific Treponema Pallidum Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Treponemal test
6.1.1.1.1. Treponema Pallidum Particle Agglutination Assay (TP-PA) Test
6.1.1.1.2. Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test
6.1.1.1.3. Treponema Pallidum Hemagglutination Assay (TPHA)
6.1.1.1.4. Others
6.1.1.2. Non-treponemal tests
6.1.1.2.1. Venereal Disease Research Laboratory (VDRL) Test
6.1.1.2.2. Rapid Plasma Reagin (RPR) Test
6.1.1.3. Toluidine Red Unheated Serum Test (TRUST)
6.2. Asia Pacific Treponema Pallidum Tests Market Outlook, by Service Provider, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Hospitals
6.2.1.2. Specialty Clinics
6.2.1.3. Ambulatory Surgical Centers
6.2.1.4. Diagnostic Laboratories
6.2.1.5. Academic & Research Institutes
6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Treponema Pallidum Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. China Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
6.3.1.2. China Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
6.3.1.3. Japan Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
6.3.1.4. Japan Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
6.3.1.5. South Korea Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
6.3.1.6. South Korea Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
6.3.1.7. India Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
6.3.1.8. India Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
6.3.1.9. Southeast Asia Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
6.3.1.10. Southeast Asia Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
6.3.1.11. Rest of Asia Pacific Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
6.3.1.12. Rest of Asia Pacific Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Treponema Pallidum Tests Market Outlook, 2018 - 2031
7.1. Latin America Treponema Pallidum Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Treponemal test
7.1.1.1.1. Treponema Pallidum Particle Agglutination Assay (TP-PA) Test
7.1.1.1.2. Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test
7.1.1.1.3. Treponema Pallidum Hemagglutination Assay (TPHA)
7.1.1.1.4. Others
7.1.1.2. Non-treponemal tests
7.1.1.2.1. Venereal Disease Research Laboratory (VDRL) Test
7.1.1.2.2. Rapid Plasma Reagin (RPR) Test
7.1.1.3. Toluidine Red Unheated Serum Test (TRUST)
7.2. Latin America Treponema Pallidum Tests Market Outlook, by Service Provider, Value (US$ Bn), 2018 - 2031
7.2.1.1. Hospitals
7.2.1.2. Specialty Clinics
7.2.1.3. Ambulatory Surgical Centers
7.2.1.4. Diagnostic Laboratories
7.2.1.5. Academic & Research Institutes
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Treponema Pallidum Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
7.3.1.2. Brazil Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
7.3.1.3. Mexico Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
7.3.1.4. Mexico Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
7.3.1.5. Argentina Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
7.3.1.6. Argentina Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
7.3.1.7. Rest of Latin America Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
7.3.1.8. Rest of Latin America Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Treponema Pallidum Tests Market Outlook, 2018 - 2031
8.1. Middle East & Africa Treponema Pallidum Tests Market Outlook, by Test Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Treponemal test
8.1.1.1.1. Treponema Pallidum Particle Agglutination Assay (TP-PA) Test
8.1.1.1.2. Fluorescent Treponemal Antibody Absorption (FTA-ABS) Test
8.1.1.1.3. Treponema Pallidum Hemagglutination Assay (TPHA)
8.1.1.1.4. Others
8.1.1.2. Non-treponemal tests
8.1.1.2.1. Venereal Disease Research Laboratory (VDRL) Test
8.1.1.2.2. Rapid Plasma Reagin (RPR) Test
8.1.1.3. Toluidine Red Unheated Serum Test (TRUST)
8.2. Middle East & Africa Treponema Pallidum Tests Market Outlook, by Service Provider, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Hospitals
8.2.1.2. Specialty Clinics
8.2.1.3. Ambulatory Surgical Centers
8.2.1.4. Diagnostic Laboratories
8.2.1.5. Academic & Research Institutes
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Treponema Pallidum Tests Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. GCC Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
8.3.1.2. GCC Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
8.3.1.3. South Africa Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
8.3.1.4. South Africa Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
8.3.1.5. Egypt Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
8.3.1.6. Egypt Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
8.3.1.7. Nigeria Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
8.3.1.8. Nigeria Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
8.3.1.9. Rest of Middle East & Africa Treponema Pallidum Tests Market by Test Type, Value (US$ Bn), 2018 - 2031
8.3.1.10. Rest of Middle East & Africa Treponema Pallidum Tests Market by Service Provider, Value (US$ Bn), 2018 - 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs by Service Provider Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Abbott Laboratories
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Siemens Healthineers AG
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Bio-Rad Laboratories Inc
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Fujirebio Inc,
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Trinity Biotech Plc
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations